Warfarin is a widely used anticoagulant with a narrow therapeutic index and large
interpatient variability in the dose required to achieve target anticoagulation. Common …

Individual variability in drug efficacy and drug safety is a major challenge in current clinical
practice, drug development, and drug regulation. For more than 5 decades, studies of …

This document is an update to the 2011 Clinical Pharmacogenetics Implementation
Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing …

Based on pre-DNA racial/color methodology, clinical and pharmacological trials have
traditionally considered the different geographical regions of Brazil as being very …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …

Oral anticoagulants are a mainstay of cardiovascular therapy, and for over 60 years vitamin
K antagonists (VKAs) were the only available agents for long-term use. VKAs interfere with …

We report the first genome-wide association study (GWAS) whose sample size (1,053
Swedish subjects) is sufficiently powered to detect genome-wide significance (p< 1.5× 10 …

Thrombosis has long been recognized as a potentially lifethreatening complication in
children with congenital heart disease (CHD), children with acquired heart disease, and in …

Summary Background VKORC1 and CYP2C9 are important contributors to warfarin dose
variability, but explain less variability for individuals of African descent than for those of …

Motivation: Widespread availability of low-cost, full genome sequencing will introduce new
challenges for bioinformatics. Results: This review outlines recent developments in …